Genelux (GNLX) said Friday that Jason Litten has been named chief medical officer, effective immediately.
Litten most recently served as chief medical officer at Chimeric Therapeutics, the company said.
Litten received an inducement award of a stock option to purchase 275,000 shares under the company's 2023 inducement plan, Genelux said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments